Enrofloxacin is a fluoroquinolone antibiotic sold by the Bayer Corporation under the trade name Baytril?. Enrofloxacin is currently FDA-approved for treatment of individual pets and domestic animals in the United States.
It is a bactericidal agent. The bactericidal activity of enrofloxacin is concentration-dependent, with susceptible bacteria cell death occurring within 20–30 minutes of exposure. Enrofloxacin has demonstrated a significant post-antibiotic effect for both Gram-negative and Gram-positive bacteria and is active in both stationary and growth phases of bacterial replication.
Enrofloxacin is a broad - spectrum bactericidal drug that has specific effects on mycoplasma. It has bactericidal effect on escherichia coli, klebsiella, salmonella, proteus, pseudomonas aeruginosa, haemophilus, pasteurella multiforme, hemolytic pasteurella, staphylococcus aureus, streptococcus and so on.
Enrofloxacin can be used as an animal drug. It has a long half-life and a good tissue distribution in animals. It is a widely available antibacterial agent.